The FDA has approved Eli Lilly’s Zepbound, a once-weekly injectable drug, for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Used in combination with a reduced-calorie diet and exercise, Zepbound can lead to improved sleep apnea and weight loss. The drug, initially developed for metabolic conditions, is the first FDA-approved therapy for sleep apnea, a condition that affects an estimated 25 million US adults and is usually managed with a medical breathing aid device.
Ascension’s Data Breach Affects Millions
Ascension, a healthcare services provider, disclosed that a ransomware attack affected 5,599,699 individuals’ data in May. The breach was triggered by a deceptive email from
